Language
English
Publication Date
1-1-2025
Journal
Nature
DOI
10.1038/s41586-024-08261-8
PMID
39604730
PMCID
PMC12704925
PubMedCentral® Posted Date
12-16-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Interleukin-15 (IL15) promotes the survival of T lymphocytes and enhances the antitumor properties of CAR T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy1-4. Glypican-3 (GPC3) is expressed in a group of solid cancers5-10, and here we report the first evaluation in humans of the effects of IL15 co-expression on GPC3-CAR T cells. Cohort 1 patients (NCT02905188/NCT02932956) received GPC3-CAR T cells, which were safe but produced no objective antitumor responses and reached peak expansion at two weeks. Cohort 2 patients (NCT05103631/NCT04377932) received GPC3-CAR T cells that co-expressed IL15 (15.CAR), which mediated significantly increased cell expansion and induced a disease control rate of 66% and antitumor response rate of 33%. Infusion of 15.CAR T cells was associated with increased incidence of cytokine release syndrome, which was rapidly ameliorated by activation of the inducible caspase 9 safety switch. Compared to non-responders, tumor-infiltrating 15.CAR T cells from responders showed repression of SWI/SNF epigenetic regulators and upregulation of FOS and JUN family members as well as genes related to type I interferon signaling. Collectively, these results demonstrate that IL15 increases the expansion, intratumoral survival, and antitumor activity of GPC3-CAR T cells in patients.
Keywords
Female, Humans, Male, Middle Aged, Cohort Studies, Cytokine Release Syndrome, Glypicans, Immunotherapy, Adoptive, Interleukin-15, Interleukin-6, Neoplasms, Receptors, Chimeric Antigen, T-Lymphocytes
Published Open-Access
yes
Recommended Citation
Steffin, David; Ghatwai, Nisha; Montalbano, Antonino; et al., "Interleukin-15-Armoured GPC3 Car T Cells for Patients With Solid Cancers" (2025). Faculty, Staff and Students Publications. 6260.
https://digitalcommons.library.tmc.edu/baylor_docs/6260